Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: SBS

CampTek Software Announces Coronavirus Conference Cancellation Bot


PORTLAND, Maine, March 12, 2020 /PRNewswire/ -- CampTek Software the leader in Robotic Process Automation (RPA) announced today that it has successfully completed a robot that will automate cancellations and refunds for large conferences around the world. Recently there have been over 260 conferences cancelled as result of the pandemic.

"We are upset to hear about the number of cancellations and the growing disruption this virus is having on the business community.  We feel compelled to do something about this growing crisis," stated Peter Camp, CTO and Founder of CampTek Software.

As an RPA SaaS Provider, CampTek Software utilizes the UiPath Enterprise Platform with its AI and Machine Learning capabilities to create the Bots that automates this high value function that would take many human workers countless hours. UiPath has recently assisted with speeding up the coronavirus diagnosis time by 50 percent for health providers. 

Regardless of the application, platform and method of delivery, CampTek Software's expertise and technical backbone will enable them to quickly respond to any need that may arise as a result of the COVID-19 outbreak.

CampTek Software is a RPA SaaS Provider offering a wide array of services to assist you on your RPA Journey. Our team of certified experts focus on Bot development, Bot Support and Hosted Support for our RPA Partners.

Media Contact:
Amy Wooldridge
VP of Operations and Customer Success
CampTek Software
[email protected]
877.272.0857 x1

SOURCE CampTek Software


These press releases may also interest you

at 01:20
Biophytis Announces Ratio Change Under its American Depositary Receipt ("ADR") Program
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 - Exclusive Report by 360iResearch
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
SETC-Assistance.org Helps Eligible Self-Employed Workers Receive Up to $32,220 in Tax Credits Through SETC Program
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDEL
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

More news about Covid-19 virus...


News published on and distributed by: